Pacira Biosciences Q3 revenue misses estimates

Pacira Biosciences

06/11/2025 21:33

Overview

Pacira Q3 revenue up 6% but missed analyst expectations

Adjusted net income and EBITDA for Q3 beat analyst estimates

The non-opioid pain therapeutics firm repurchased 2 mln shares for $50 mln in Q3

Outlook

Pacira updates 2025 revenue guidance to $725 mln-$735 mln, down from $730 mln-$750 mln

Pacira raises 2025 non-GAAP gross margin guidance to 80%-82% from 78%-80%

Company expects non-GAAP R&D expenses of $95 mln-$105 mln for 2025

Result Drivers

EXPAREL VOLUME GROWTH - 9% increase in EXPAREL volume drove revenue growth, partially offset by vial mix shift and discounting from new GPO partnership

5x30 STRATEGY - Key milestones in 5x30 growth strategy, including patient enrollment conclusion and exclusive license agreement for AMT-143, advanced growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$179.50 mln
$182.55 mln (6 Analysts)
Q3 Adjusted Net Income
Beat
$31.80 mln
$31.44 mln (5 Analysts)
Q3 Net Income
$5.40 mln
Q3 Adjusted EBITDA
Beat
$49.40 mln
$46.50 mln (5 Analysts)
Q3 Cash & Investments
$246.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Pacira Biosciences Inc is $30.00, about 27.2% above its November 5 closing price of $21.85

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release: ID:nGNX7QwFvG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)